文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

低密度脂蛋白胆固醇清除减少与脓毒性休克死亡率增加存在因果关联

Decreased Clearance of Low-Density Lipoprotein Cholesterol is Causally Associated With Increased Mortality of Septic Shock.
PubMed 文献 · Crit Care Med · 2025-08-05
一句话结论基因预测感染前LDL-C水平升高与脓毒性休克28天死亡率增加存在因果关联(HR 2.78),机制为LDL-C清除减少而非生成增多。

该研究在日本多中心ICU纳入614例基因分型的脓毒性休克患者,利用超过15万日本人群的GWAS汇总数据基因预测感染前LDL-C水平,采用两样本孟德尔随机化评估其与28天死亡率的因果关联。结果发现基因预测感染前LDL-C水平(141 mg/dL)远高于休克起病时实测LDL-C水平(40 mg/dL,p<0.001),且高基因预测感染前LDL-C水平与28天死亡率增加存在因果关联(HR 2.78,p=0.039)。通过PCSK9和HMGCR基因型分析,发现增加LDL受体介导LDL-C清除的PCSK9变异与死亡率降低相关(p=0.003),而减少LDL-C生成的HMGCR变异与死亡率降低无关(观察到相反效应,p=0.039)。作者认为增强LDL受体介导的病原体脂质毒素清除可能改善脓毒性休克结局。

要点

  • 基因预测感染前LDL-C水平与脓毒性休克28天死亡率存在因果关联(HR 2.78,p=0.039)。
  • 脓毒性休克起病时实测LDL-C(40 mg/dL)远低于基因预测感染前水平(141 mg/dL,p<0.001)。
  • 增加LDL受体介导LDL-C清除的PCSK9变异与死亡率降低相关(p=0.003)。
  • 减少LDL-C生成的HMGCR变异与死亡率降低无关,观察到相反效应(p=0.039)。
  • 驱动关联的主要变异位于载脂蛋白基因ApoB100-rs13306206和ApoE-rs7412,均与LDL受体结合LDL-C相关。

适用人群与场景

  • 日本多中心ICU中基因分型的脓毒性休克患者(n=614)。

研究设计与关键结果

  • 研究类型为基因关联研究结合两样本孟德尔随机化,纳入日本多中心ICU的614例基因分型脓毒性休克患者,无干预。
  • 基因预测感染前LDL-C水平为141 mg/dL,直接测定的脓毒性休克起病时LDL-C水平为40 mg/dL,前者远高于后者(p<0.001)。
  • 两样本孟德尔随机化显示高基因预测感染前LDL-C水平与脓毒性休克28天死亡率增加存在因果关联(HR 2.78,p=0.039)。
  • 通过LDL受体增加LDL-C清除的PCSK9基因变异(基因模拟PCSK9抑制剂治疗)与死亡率降低相关(p=0.003)。
  • 减少LDL-C生成的HMGCR基因变异(基因模拟他汀治疗)与脓毒性休克死亡率降低无关,观察到相反效应(p=0.039)。
  • 高基因预测感染前LDL-C水平与死亡率增加关联的主要驱动变异为载脂蛋白基因ApoB100-rs13306206和ApoE-rs7412,这些载脂蛋白参与LDL-C与LDL受体结合。

证据类型、等级与局限

  • 证据类型:基因关联研究结合两样本孟德尔随机化。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,增强LDL受体介导的病原体脂质毒素清除可能改善脓毒性休克结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine whether low-density lipoprotein cholesterol (LDL-C) levels, set by the balance of clearance and production, causally contribute to septic shock 28-day mortality.

DESIGN: We measured LDL-C levels and genotypes in patients with septic shock. Using Genotyping and Genome-Wide Association Study summary statistics from over 150,000 Japanese participants, we genetically predicted pre-infection LDL-C levels. Two-sample Mendelian randomization was used to assess the causal relationship between predicted pre-infection LDL-C levels and 28-day mortality. We analyzed PCSK9 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) genotypes to determine if LDL-C clearance or production was the underlying mechanism.

SETTING: Multicenter ICUs in Japan.

PATIENTS: Genotyped septic shock patients ( n = 614).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Predicted pre-infection LDL-C levels were much higher than directly measured LDL-C levels at the onset of septic shock (141 mg/dL vs. 40 mg/dL, p < 0.001). Two-sample Mendelian randomization revealed that high predicted pre-infection LDL-C levels were causally associated with increased septic shock 28-day mortality (hazard ratio, 2.78; p = 0.039). PCSK9 genetic variants that increase LDL-C clearance via the LDL receptor (genetically proxied PCSK9 inhibitor treatment) were associated with decreased mortality ( p = 0.003) while HMGCR genetic variants that decrease LDL-C production (genetically proxied statin treatment) were not associated with decreased septic shock mortality (indeed the opposite effect was observed, p = 0.039). The two main genetic variants driving the association between high predicted pre-infection LDL-C levels and increased mortality were in apolipoprotein genes ( ApoB100 -rs13306206 and ApoE -rs7412), apolipoproteins involved in LDL-C binding to the LDL receptor.

CONCLUSIONS: Low LDL-C clearance explains the causal association between high genetically predicted pre-infection LDL-C levels and increased septic shock mortality. PCSK9 , ApoB , and ApoE variants were identified as causal, all related to the LDL receptor or its interaction with LDL-C. Enhancing LDL receptor-mediated clearance of pathogen lipid toxins may improve septic shock outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Takahashi N, Campbell KR, Nakada TA, et al. Decreased Clearance of Low-Density Lipoprotein Cholesterol is Causally Associated With Increased Mortality of Septic Shock. Crit Care Med. 2025. PMID: 40758386. doi:10.1097/CCM.0000000000006809

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。